Watch for the Nov 6 special meeting outcome — if all proposals pass, expect massive near-term dilution as CVP affiliates exchange preferred/debt for common shares at prices as low as $1.00, and the ELOC becomes active at $1.10 floor. The company's ability to maintain Nasdaq listing is in question given the 9th reverse split authorization and prior failed quorum. Monitor for any strategic alternative announcement (merger, reverse merger) that the company cites as a rationale for the warrant repricing.
Price Chart
Executive Summary
Jaguar Health is holding a special meeting on November 6, 2026, to seek stockholder approval for six proposals that are collectively highly dilutive and signal severe financial distress: (1) authorizing the issuance of up to ~65% of outstanding common stock to CVP affiliates via Series Q preferred and debt exchange; (2) repricing deeply out-of-the-money warrants (exercise prices $525-$3,996.60) to $1.00 to induce exercise; (3) increasing the equity incentive plan by 378,859 shares (14% of fully diluted shares); (4) authorizing a reverse stock split of up to 1-for-150; (5) lowering the ELOC floor price from $16.50 to $1.10; and (6) adjournment authority. The company has already executed eight prior reverse splits, the stock closed at $2.75 on Sept 17, 2026, and a prior special meeting failed due to lack of quorum. This is a capital-strapped micro-cap seeking to unlock massive dilution to stay listed and fund operations.
Key Facts
- Proposal 1: Full exchange of Series Q preferred and CVP debt could issue up to 25,390,851 shares (92.9% of outstanding at $1.00 hypothetical price), giving CVP affiliates ~65.4% control.
- Proposal 2: Repricing 4,052 warrants from $525-$3,996.60 to $1.00, plus associated Series O and R conversion shares, could issue up to 69,950 shares total.
- Proposal 3: Increase equity plan to 378,859 shares (14% of fully diluted shares as of Sept 30, 2026).
- Proposal 4: Authorize reverse stock split up to 1-for-150, the 9th such split; stock closed at $2.75 on Sept 17, 2026.
- Proposal 5: Lower ELOC floor price from $16.50 to $1.10, enabling up to $40M in potential share sales at deeply discounted prices.
- Record date: Sept 15, 2026; 7,802,102 common shares outstanding pre-split (520,140 post 1-for-15 split).
- Prior special meeting on Sept 4, 2026 failed due to lack of quorum; company retained Georgeson LLC for proxy solicitation at $8,500 base fee.
- 8 prior reverse stock splits executed since 2018; company acknowledges post-split price declines have occurred historically.
- Management and directors collectively own less than 1% of outstanding common stock (9,658 shares).
- 5% holders: Streeterville Capital (8.2% common, 42.4% Series Q), Uptown Capital (57.6% Series Q), Lincoln Alternative Strategies (7.14% common), Joshua Mailman (9.99% common).
Financial Impact
Potential dilution of up to 92.9% of outstanding common stock from Proposal 1 alone at $1.00 exchange price; combined with warrant exercises and ELOC draws, total dilution could exceed 95% of current float. No revenue or earnings figures provided in filing.
Risk Factors
- Massive dilution: up to 92.9% of current common shares could be issued under Proposal 1 alone, severely diluting existing holders.
- Loss of control: CVP affiliates could hold ~65.4% of common stock post-exchange, effectively controlling the company.
- Nasdaq delisting risk: stock at $2.75 post 1-for-15 split; if price declines further, the 1-for-150 reverse split authorization signals high delisting probability.
- Failed quorum risk: prior special meeting failed due to lack of quorum; this meeting may face same issue, delaying critical capital access.
- Historical reverse split failure: company acknowledges 8 prior reverse splits have been followed by price declines, suggesting this split may not stabilize the stock.
- ELOC at $1.10 floor: enables continuous selling pressure at deeply discounted prices, further depressing the stock.
- Insider ownership <1%: management has negligible skin in the game, misaligned with common shareholders.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-417938 |
| Document: 0001193125-26-417938-index-headers.html | 0001193125-26-417938 |
| Document: 0001193125-26-417938-index.html | 0001193125-26-417938 |
| Document: 0001193125-26-417938.txt | 0001193125-26-417938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | S-3 | $2.13 | awaiting T+60 | — | $2.36 (−10.92%) |
Oct 8, 2026 17d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.36 (+50.68%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.36 (+50.05%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.36 (+60.76%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.36 (+69.32%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.36 (+66.54%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.36 (+66.54%) |
Sep 21, 2026 4w ago | 8-K | $34.46 | awaiting T+60 | — | $2.36 (−93.14%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.36 (−951.87%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.36 (+77.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers